Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Anti-progesterones].

R Sitruk-Ware1

  • 1Service d'Endocrinologie, Hôpital Saint-Antoine, Paris.

Presse Medicale (Paris, France : 1983)
|December 29, 1999
PubMed
Summary

Antiprogestins, like mifepristone, show promise in reproductive health and certain cancers. Clinical studies highlight their efficacy in pregnancy termination and potential for treating uterine conditions and rare tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combined nestorone-testosterone gel suppresses serum gonadotropins to concentrations associated with effective hormonal contraception in men.

Andrology·2019
Same author

Preventing secondary exposure to women from men applying a novel nestorone/testosterone contraceptive gel.

Andrology·2018
Same author

Non-clinical studies of progesterone.

Climacteric : the journal of the International Menopause Society·2018
Same author

Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study.

Contraception·2018
Same author

Neurosteroidogenesis and progesterone anti-inflammatory/neuroprotective effects.

Journal of neuroendocrinology·2017
Same author

Impact of various progestins with or without transdermal testosterone on gonadotropin levels for non-invasive hormonal male contraception: a randomized clinical trial.

Andrology·2017

Area of Science:

  • Pharmacology and Therapeutics
  • Reproductive Medicine
  • Oncology

Context:

  • Antiprogestins represent a significant therapeutic class, with mifepristone being the primary agent in clinical use.
  • The established role of antiprogestins extends beyond pregnancy management to potential applications in gynecological conditions and oncology.

Purpose:

  • To review the characteristics of various antiprogestins.
  • To present key findings from clinical studies on mifepristone for its approved indications.
  • To explore the therapeutic potential of antiprogestins in reproductive health and cancer treatment.

Summary:

  • Mifepristone is the leading antiprogestin, approved for medical pregnancy termination, cervical dilation, and labor induction.
  • Antiprogestins demonstrate potential utility in contraception, treatment of uterine leiomyomas and endometriosis.
  • These agents show promise for treating rare progesterone receptor-expressing tumors like meningiomas and leiomyosarcomas.

Impact:

  • Provides a comprehensive overview of antiprogestin applications in reproductive health and oncology.
  • Highlights the clinical efficacy and therapeutic versatility of mifepristone.
  • Underscores the expanding role of antiprogestins in women's health and cancer therapy.

Related Experiment Videos